Home |Contact |Careers |News | Log in
Please fill name field
Please enter the numbers: Please enter the numbers
Please enter the correct digits
Your message was sent successfully


The company was founded in 1992 as a business unit within IMI, the corporate R&D center of Israel Chemicals (ICL).  The unit was tasked with peptide process development and peptide R&D targeting the pharmaceutical industry. Following several years of successful projects as a CMO, the business unit was spun-out of ICL and Novetide was incorporated as a separate business entity.

In 2000, following several years of successful projects as a CMO, the company entered into a strategic partnership with Teva Pharmaceuticals which acquired 50% of Novetide.

Novetide's R&D facility is still located within the ICL complex in Haifa where Novetide has access to a world class R&D infrastructure and cutting edge organic chemistry R&D research, support and equipment. 

Novetide works closely with TAPI, Teva's API division, which provides global marketing, sales, logistics and regulatory support.  TAPI, the leading global supplier of active pharmaceutical ingredients (APIs) TAPI has over $747 million in annual sales and more than 75 years of experience.



Following is a timeline of key events in Novetide's history:

1992 IMI's R&D peptide group is formed
1999 Novetide established
2000 Teva's strategic partnership formed
2001 TevaTech production plant built
2003 First US DMF filed
2005 First product launched in the US.
Plantex pilot plant built
2007 First product launched in the EU.
TevaTech plant expansion
2009 Plantex high capacity plant built
Plantex production site inspected by FDA
2010 First CMO project enters phase III trials
2011 TevaTech plant 2nd expansion
2012 Production capacity increased for TevaTech and Plantex production sites
Management Team Shareholders History IP Project Management Peptide Partnership Company Profile